These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38934347)

  • 21. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set.
    Wolfe CE; Wood DM; Dines A; Whatley BP; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Dargan PI;
    Neurotoxicology; 2019 Jul; 73():183-187. PubMed ID: 30974132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
    Abouchedid R; Ho JH; Hudson S; Dines A; Archer JR; Wood DM; Dargan PI
    J Med Toxicol; 2016 Dec; 12(4):396-401. PubMed ID: 27456262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
    Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
    Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
    Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
    Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
    Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
    Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.
    King A; Hill SL; Pucci M; Bailey G; Keating L; Macfarlane R; Cantle F; Hudson S; Thomas SHL
    Clin Toxicol (Phila); 2022 Oct; 60(10):1094-1098. PubMed ID: 35943421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.
    Palamar JJ; Su MK; Hoffman RS
    Am J Drug Alcohol Abuse; 2016; 42(1):39-47. PubMed ID: 26678258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies.
    Obafemi AI; Kleinschmidt K; Goto C; Fout D
    J Med Toxicol; 2015 Dec; 11(4):426-9. PubMed ID: 25967137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Severity of emergency department presentations due to acute drug toxicity in Europe: a longitudinal analysis over a 6-year period (2014-2019) stratified by sex.
    Miró Ò; Burillo-Putze G; Schmid Y; Salgado E; Liechti ME; Dines AM; Giraudon I; Heyerdahl F; Hovda KE; Vallersne OM; Eyer F; Wood DM; Yates C; Dargan PI; Galicia M;
    Eur J Emerg Med; 2023 Feb; 30(1):21-31. PubMed ID: 36350710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN Cohort.
    Brandehoff N; Adams A; McDaniel K; Banister SD; Gerona R; Monte AA
    Clin Toxicol (Phila); 2018 Mar; 56(3):193-198. PubMed ID: 28862050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European emergency departments.
    Miró Ò; Waring WS; Dargan PI; Wood DM; Dines AM; Yates C; Giraudon I; Moughty A; O'Connor N; Heyerdahl F; Hovda KE; Vallersnes OM; Paasma R; Pold K; Jürgens G; Megarbane B; Anand JS; Liakoni E; Liechti M; Eyer F; Zacharov S; Caganova B; Bonnici J; Radenkova-Saeva J; Galicia M;
    Clin Toxicol (Phila); 2021 Oct; 59(10):896-904. PubMed ID: 33724118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interpreting mono- and poly-SCRA intoxications from an activity-based point of view: JWH-018 equivalents in serum as a comparative measure.
    Janssens LK; Sommer MJ; Grafinger KE; Hermanns-Clausen M; Auwärter V; Stove CP
    Arch Toxicol; 2024 Oct; 98(10):3337-3350. PubMed ID: 39115690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.